Focus: Triveni Bio is a precision medicine biotech focused on genetics-informed therapeutics in oncology and rare diseases, operating as a public company from Watertown, MA since 1993.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Best suited for scientists seeking precision-medicine exposure and strong VC backing, but limited hiring and opaque pipeline depth create execution uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Triveni Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Triveni Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Which biotechs have raised new VC financing this week? - pharmaphorum
Which biotechs have raised new VC financing this week? pharmaphorum
Triveni Bio Raises $65M Series C Co-Led by Ascenta, Henderson Investors - citybiz
Triveni Bio Raises $65M Series C Co-Led by Ascenta, Henderson Investors citybiz
Triveni Bio Raises $65M in Series C Funding - FinSMEs
Triveni Bio Raises $65M in Series C Funding FinSMEs
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth - PR Newswire
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth PR Newswire
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs - Endpoints News
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs Endpoints News
J&J buys Firefly Bio to strengthen oncology pipeline - The Pharma Letter
J&J buys Firefly Bio to strengthen oncology pipeline The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
The AhR regulates IFN-induced immune checkpoints in lung cancer cells through HNRNPH1, an RNA-binding protein, and INCR1, a novel long non-coding RNA.
Thermostable lamprey variable lymphocyte receptor antibody for detection of Plasmodium falciparum histidine rich protein-2.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo